119 related articles for article (PubMed ID: 15289786)
21. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
Gibbs JP; Hyland R; Youdim K
Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
[TBL] [Abstract][Full Text] [Related]
22. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.
Le Corre P; Parmer RJ; Kailasam MT; Kennedy BP; Skaar TP; Ho H; Leverge R; Smith DW; Ziegler MG; Insel PA; Schork NJ; Flockhart DA; O'connor DT
Clin Pharmacol Ther; 2004 Aug; 76(2):139-53. PubMed ID: 15289791
[TBL] [Abstract][Full Text] [Related]
23. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.
Moller RA; Fisher JM; Taylor AE; Kolluri S; Gardner MJ; Obach RS; Walsky RL
Ann Pharmacother; 2006 Jan; 40(1):32-7. PubMed ID: 16368922
[TBL] [Abstract][Full Text] [Related]
24. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis.
Nafziger AN; Bertino JS
Clin Pharmacol Ther; 2007 Oct; 82(4):379; author reply 380. PubMed ID: 17851579
[No Abstract] [Full Text] [Related]
25. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics.
Liangpunsakul S; Kolwankar D; Pinto A; Gorski JC; Hall SD; Chalasani N
Hepatology; 2005 May; 41(5):1144-50. PubMed ID: 15841467
[TBL] [Abstract][Full Text] [Related]
26. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
27. Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues.
Huang Z; Fasco MJ; Spivack S; Kaminsky LS
Cancer Res; 1997 Jul; 57(13):2589-92. PubMed ID: 9205060
[TBL] [Abstract][Full Text] [Related]
28. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.
Ma JD; Nafziger AN; Rhodes G; Liu S; Gartung AM; Bertino JS
J Clin Pharmacol; 2006 Jan; 46(1):103-8. PubMed ID: 16397289
[TBL] [Abstract][Full Text] [Related]
29. Genes and the response to drugs.
Caraco Y
N Engl J Med; 2004 Dec; 351(27):2867-9. PubMed ID: 15625340
[No Abstract] [Full Text] [Related]
30. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.
Bernard S; Neville KA; Nguyen AT; Flockhart DA
Oncologist; 2006 Feb; 11(2):126-35. PubMed ID: 16476833
[TBL] [Abstract][Full Text] [Related]
31. Is genetic testing for cytochrome P450 polymorphisms ready for implementation?
Matchar DB; Thakur M
Am Fam Physician; 2007 Aug; 76(3):348, 351. PubMed ID: 17708133
[No Abstract] [Full Text] [Related]
32. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
33. Screening for cytochrome P450 3A in man: studies with midazolam and nifedipine.
Yeates RA; Scharpf F; Laufen H; Zimmermann T
J Pharm Pharmacol; 1996 Sep; 48(9):933-4. PubMed ID: 8910856
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
Ingelman-Sundberg M
Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
[TBL] [Abstract][Full Text] [Related]
35. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
[TBL] [Abstract][Full Text] [Related]
36. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein.
Cummins CL; Wu CY; Benet LZ
Clin Pharmacol Ther; 2002 Nov; 72(5):474-89. PubMed ID: 12426511
[No Abstract] [Full Text] [Related]
37. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
38. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene].
Bozina N; Tramisak I; Granić P; Puljević D; Stavljenić-Rukavina A
Lijec Vjesn; 2002; 124(3-4):63-6. PubMed ID: 18958918
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 3A pharmacogenetics: the road that needs traveled.
Flockhart DA; Rae JM
Pharmacogenomics J; 2003; 3(1):3-5. PubMed ID: 12629575
[No Abstract] [Full Text] [Related]
40. [Pharmacogenetics--pathway to individualized antihypertensive pharmacotherapy].
Kurland L; Lind L; Lithell H; Syvänen AC; Melhus H
Lakartidningen; 2003 Feb; 100(8):600-3. PubMed ID: 12640971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
